tiprankstipranks
Trending News
More News >
Tourmaline Bio (TRML)
NASDAQ:TRML
US Market

Tourmaline Bio (TRML) Stock Forecast & Price Target

Compare
541 Followers
See the Price Targets and Ratings of:

TRML Analyst Ratings

Strong Buy
11Ratings
Strong Buy
11 Buy
0 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Tourmaline
Bio
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TRML Stock 12 Month Forecast

Average Price Target

$54.89
▲(220.81%Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Tourmaline Bio in the last 3 months. The average price target is $54.89 with a high forecast of $70.00 and a low forecast of $35.00. The average price target represents a 220.81% change from the last price of $17.11.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","71":"$71","26.75":"$26.8","41.5":"$41.5","56.25":"$56.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$54.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,26.75,41.5,56.25,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.85,21.861538461538462,25.873076923076923,29.884615384615387,33.89615384615385,37.90769230769231,41.91923076923077,45.93076923076923,49.94230769230769,53.95384615384616,57.965384615384615,61.97692307692308,65.98846153846154,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.85,20.69923076923077,23.548461538461538,26.39769230769231,29.24692307692308,32.09615384615385,34.94538461538462,37.79461538461538,40.643846153846155,43.49307692307693,46.34230769230769,49.191538461538464,52.040769230769236,{"y":54.89,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.85,19.169230769230772,20.48846153846154,21.80769230769231,23.126923076923077,24.446153846153848,25.76538461538462,27.084615384615386,28.403846153846153,29.723076923076924,31.042307692307695,32.36153846153846,33.68076923076923,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.59,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.54,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.71,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.34,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.23,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.66,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$70.00Average Price Target$54.89Lowest Price Target$35.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on TRML
Yi ChenH.C. Wainwright
H.C. Wainwright
$50
Buy
192.23%
Upside
Reiterated
05/27/25
Promising Phase 2 Trial Results and Strategic Advantages Justify Buy Rating for Tourmaline Bio
Leerink Partners Analyst forecast on TRML
Thomas SmithLeerink Partners
Leerink Partners
$49$54
Buy
215.60%
Upside
Reiterated
05/22/25
Tourmaline Bio (TRML) PT Raised to $54 at Leerink PartnersLeerink Partners analyst Thomas Smith raised the price target on Tourmaline Bio (NASDAQ: TRML) to $54.00 (from $49.00) while maintaining a Outperform rating.
Truist Financial Analyst forecast on TRML
Srikripa DevarakondaTruist Financial
Truist Financial
Buy
Reiterated
05/21/25
Truist Financial Keeps Their Buy Rating on Tourmaline Bio (TRML)
LifeSci Capital Analyst forecast on TRML
Rami KatkhudaLifeSci Capital
LifeSci Capital
$58
Buy
238.98%
Upside
Reiterated
05/20/25
Buy Rating for Tourmaline Bio Driven by Promising Clinical Results and Market Potential
BMO Capital Analyst forecast on TRML
Kostas BiliourisBMO Capital
BMO Capital
$35
Buy
104.56%
Upside
Reiterated
05/20/25
Promising Potential of Tourmaline Bio's TOUR006: A Strong Buy Recommendation
Guggenheim Analyst forecast on TRML
Unknown AnalystGuggenheim
Not Ranked
Guggenheim
$55
Buy
221.45%
Upside
Reiterated
05/04/25
Cantor Fitzgerald Analyst forecast on TRML
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
04/23/25
Cantor Fitzgerald reiterates Overweight Rating on Tourmaline Bio (TRML)Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and {REMOVEPT} price target on Tourmaline Bio (NASDAQ: TRML).
Chardan Capital Analyst forecast on TRML
Daniil GataulinChardan Capital
Chardan Capital
$70
Buy
309.12%
Upside
Initiated
04/22/25
Tourmaline Bio (TRML) Gets a Buy from Chardan Capital
Jefferies Analyst forecast on TRML
Roger SongJefferies
Jefferies
$64
Buy
274.05%
Upside
Reiterated
04/21/25
Tourmaline Bio's Strategic Advancements and Financial Strength Drive Buy Rating
Wedbush
$42$43
Buy
151.32%
Upside
Reiterated
03/14/25
Tourmaline Bio (TRML) Gets a Buy from Wedbush
Piper Sandler Analyst forecast on TRML
Yasmeen RahimiPiper Sandler
Piper Sandler
$65
Buy
279.89%
Upside
Reiterated
03/10/25
Piper Sandler Sticks to Their Buy Rating for Tourmaline Bio (TRML)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on TRML
Yi ChenH.C. Wainwright
H.C. Wainwright
$50
Buy
192.23%
Upside
Reiterated
05/27/25
Promising Phase 2 Trial Results and Strategic Advantages Justify Buy Rating for Tourmaline Bio
Leerink Partners Analyst forecast on TRML
Thomas SmithLeerink Partners
Leerink Partners
$49$54
Buy
215.60%
Upside
Reiterated
05/22/25
Tourmaline Bio (TRML) PT Raised to $54 at Leerink PartnersLeerink Partners analyst Thomas Smith raised the price target on Tourmaline Bio (NASDAQ: TRML) to $54.00 (from $49.00) while maintaining a Outperform rating.
Truist Financial Analyst forecast on TRML
Srikripa DevarakondaTruist Financial
Truist Financial
Buy
Reiterated
05/21/25
Truist Financial Keeps Their Buy Rating on Tourmaline Bio (TRML)
LifeSci Capital Analyst forecast on TRML
Rami KatkhudaLifeSci Capital
LifeSci Capital
$58
Buy
238.98%
Upside
Reiterated
05/20/25
Buy Rating for Tourmaline Bio Driven by Promising Clinical Results and Market Potential
BMO Capital Analyst forecast on TRML
Kostas BiliourisBMO Capital
BMO Capital
$35
Buy
104.56%
Upside
Reiterated
05/20/25
Promising Potential of Tourmaline Bio's TOUR006: A Strong Buy Recommendation
Guggenheim Analyst forecast on TRML
Unknown AnalystGuggenheim
Not Ranked
Guggenheim
$55
Buy
221.45%
Upside
Reiterated
05/04/25
Cantor Fitzgerald Analyst forecast on TRML
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
04/23/25
Cantor Fitzgerald reiterates Overweight Rating on Tourmaline Bio (TRML)Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and {REMOVEPT} price target on Tourmaline Bio (NASDAQ: TRML).
Chardan Capital Analyst forecast on TRML
Daniil GataulinChardan Capital
Chardan Capital
$70
Buy
309.12%
Upside
Initiated
04/22/25
Tourmaline Bio (TRML) Gets a Buy from Chardan Capital
Jefferies Analyst forecast on TRML
Roger SongJefferies
Jefferies
$64
Buy
274.05%
Upside
Reiterated
04/21/25
Tourmaline Bio's Strategic Advancements and Financial Strength Drive Buy Rating
Wedbush
$42$43
Buy
151.32%
Upside
Reiterated
03/14/25
Tourmaline Bio (TRML) Gets a Buy from Wedbush
Piper Sandler Analyst forecast on TRML
Yasmeen RahimiPiper Sandler
Piper Sandler
$65
Buy
279.89%
Upside
Reiterated
03/10/25
Piper Sandler Sticks to Their Buy Rating for Tourmaline Bio (TRML)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tourmaline Bio

1 Month
xxx
Success Rate
4/7 ratings generated profit
57%
Average Return
+20.93%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +20.93% per trade.
3 Months
xxx
Success Rate
4/7 ratings generated profit
57%
Average Return
+27.24%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +27.24% per trade.
1 Year
Srikripa DevarakondaTruist Financial
Success Rate
7/11 ratings generated profit
64%
Average Return
+7.08%
reiterated a buy rating 15 days ago
Copying Srikripa Devarakonda's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +7.08% per trade.
2 Years
xxx
Success Rate
7/11 ratings generated profit
64%
Average Return
+9.63%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of +9.63% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TRML Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
7
5
10
13
21
Buy
3
2
2
3
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
7
12
16
24
In the current month, TRML has received 24 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TRML average Analyst price target in the past 3 months is 54.89.
Each month's total comprises the sum of three months' worth of ratings.

TRML Financial Forecast

TRML Earnings Forecast

Next quarter’s earnings estimate for TRML is -$0.93 with a range of -$1.05 to -$0.78. The previous quarter’s EPS was -$0.89. TRML beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year TRML has Outperformed its overall industry.
Next quarter’s earnings estimate for TRML is -$0.93 with a range of -$1.05 to -$0.78. The previous quarter’s EPS was -$0.89. TRML beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year TRML has Outperformed its overall industry.
No data currently available

TRML Sales Forecast

Next quarter’s sales forecast for TRML is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TRML beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year TRML has Preformed in-line its overall industry.
Next quarter’s sales forecast for TRML is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TRML beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year TRML has Preformed in-line its overall industry.

TRML Stock Forecast FAQ

What is TRML’s average 12-month price target, according to analysts?
Based on analyst ratings, Tourmaline Bio’s 12-month average price target is 54.89.
    What is TRML’s upside potential, based on the analysts’ average price target?
    Tourmaline Bio has 220.81% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TRML a Buy, Sell or Hold?
          Tourmaline Bio has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Tourmaline Bio’s price target?
            The average price target for Tourmaline Bio is 54.89. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $70.00 ,the lowest forecast is $35.00. The average price target represents 220.81% Increase from the current price of $17.11.
              What do analysts say about Tourmaline Bio?
              Tourmaline Bio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of TRML?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis